Smart for Life (SMFL) Competitors

Smart for Life logo
$0.0002 0.00 (0.00%)
As of 11/16/2026

SMFL vs. SISI, BPTH, SYRS, TRVN, and SXTC

Should you buy Smart for Life stock or one of its competitors? Smart for Life's main competitors and comparable companies include Shineco (SISI), Bio-Path (BPTH), Syros Pharmaceuticals (SYRS), Trevena (TRVN), and China SXT Pharmaceuticals (SXTC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Smart for Life compare to Shineco?

Shineco (NASDAQ:SISI) and Smart for Life (NASDAQ:SMFL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

4.1% of Shineco shares are owned by institutional investors. Comparatively, 28.4% of Smart for Life shares are owned by institutional investors. 0.0% of Shineco shares are owned by company insiders. Comparatively, 31.7% of Smart for Life shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Smart for Life had 1 more articles in the media than Shineco. MarketBeat recorded 1 mentions for Smart for Life and 0 mentions for Shineco. Shineco's average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Shineco Neutral
Smart for Life Neutral

Smart for Life has a net margin of 0.00% compared to Shineco's net margin of -380.55%. Smart for Life's return on equity of 0.00% beat Shineco's return on equity.

Company Net Margins Return on Equity Return on Assets
Shineco-380.55% -79.89% -33.01%
Smart for Life N/A N/A N/A

Shineco has a beta of -43.7, indicating that its stock price is 4,470% less volatile than the broader market. Comparatively, Smart for Life has a beta of 17.84, indicating that its stock price is 1,684% more volatile than the broader market.

Shineco has higher earnings, but lower revenue than Smart for Life. Shineco is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shineco$9.60M0.00-$22.45M-$204.00N/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

Summary

Smart for Life beats Shineco on 10 of the 12 factors compared between the two stocks.

How does Smart for Life compare to Bio-Path?

Bio-Path (NASDAQ:BPTH) and Smart for Life (NASDAQ:SMFL) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 28.4% of Smart for Life shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by company insiders. Comparatively, 31.7% of Smart for Life shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Bio-Path has higher earnings, but lower revenue than Smart for Life. Bio-Path is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-PathN/AN/A-$16.08M-$1.09N/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

In the previous week, Smart for Life had 1 more articles in the media than Bio-Path. MarketBeat recorded 1 mentions for Smart for Life and 0 mentions for Bio-Path. Bio-Path's average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Bio-Path Neutral
Smart for Life Neutral

Smart for Life's return on equity of 0.00% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-PathN/A -2,842.40% -337.48%
Smart for Life N/A N/A N/A

Bio-Path has a beta of -0.8, meaning that its stock price is 180% less volatile than the broader market. Comparatively, Smart for Life has a beta of 17.84, meaning that its stock price is 1,684% more volatile than the broader market.

Summary

Smart for Life beats Bio-Path on 8 of the 10 factors compared between the two stocks.

How does Smart for Life compare to Syros Pharmaceuticals?

Smart for Life (NASDAQ:SMFL) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

Smart for Life's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Syros Pharmaceuticals N/A -3,369.56%-97.04%

Smart for Life has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Syros Pharmaceuticals$386K0.01-$164.57M-$3.03N/A

28.4% of Smart for Life shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 31.7% of Smart for Life shares are held by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Smart for Life has a beta of 17.84, indicating that its stock price is 1,684% more volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market.

In the previous week, Smart for Life had 1 more articles in the media than Syros Pharmaceuticals. MarketBeat recorded 1 mentions for Smart for Life and 0 mentions for Syros Pharmaceuticals. Smart for Life's average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Syros Pharmaceuticals Neutral

Summary

Smart for Life beats Syros Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does Smart for Life compare to Trevena?

Smart for Life (NASDAQ:SMFL) and Trevena (NASDAQ:TRVN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Smart for Life has higher revenue and earnings than Trevena. Smart for Life is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Trevena$443K0.00-$40.29M-$47.04N/A

In the previous week, Smart for Life had 1 more articles in the media than Trevena. MarketBeat recorded 1 mentions for Smart for Life and 0 mentions for Trevena. Smart for Life's average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Trevena Neutral

Smart for Life has a beta of 17.84, indicating that its stock price is 1,684% more volatile than the broader market. Comparatively, Trevena has a beta of -1.83, indicating that its stock price is 283% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Trevena N/A N/A -119.55%

28.4% of Smart for Life shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 31.7% of Smart for Life shares are held by insiders. Comparatively, 2.7% of Trevena shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Smart for Life beats Trevena on 8 of the 10 factors compared between the two stocks.

How does Smart for Life compare to China SXT Pharmaceuticals?

China SXT Pharmaceuticals (NASDAQ:SXTC) and Smart for Life (NASDAQ:SMFL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

Company Net Margins Return on Equity Return on Assets
China SXT PharmaceuticalsN/A N/A N/A
Smart for Life N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Smart for Life
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

5.0% of China SXT Pharmaceuticals shares are held by institutional investors. Comparatively, 28.4% of Smart for Life shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by company insiders. Comparatively, 31.7% of Smart for Life shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

China SXT Pharmaceuticals has a beta of 2.02, suggesting that its stock price is 102% more volatile than the broader market. Comparatively, Smart for Life has a beta of 17.84, suggesting that its stock price is 1,684% more volatile than the broader market.

China SXT Pharmaceuticals has higher earnings, but lower revenue than Smart for Life.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China SXT Pharmaceuticals$1.14M0.26-$6.20MN/AN/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

In the previous week, China SXT Pharmaceuticals had 2 more articles in the media than Smart for Life. MarketBeat recorded 3 mentions for China SXT Pharmaceuticals and 1 mentions for Smart for Life. China SXT Pharmaceuticals' average media sentiment score of 0.93 beat Smart for Life's score of 0.00 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
China SXT Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Smart for Life
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

China SXT Pharmaceuticals beats Smart for Life on 5 of the 9 factors compared between the two stocks.

Get Smart for Life News Delivered to You Automatically

Sign up to receive the latest news and ratings for SMFL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMFL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SMFL vs. The Competition

MetricSmart for LifePharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1K$13.66B$7.78B$11.73B
Dividend YieldN/A2.58%2.46%4.43%
P/E Ratio0.0029.4634.3130.02
Price / Sales0.007.098.515.65
Price / CashN/A15.7421.9322.50
Price / Book0.004.834.333.70
Net Income-$22.68M$2.88B$3.51B$392.17M
7 Day PerformanceN/A-3.17%-4.62%-3.17%
1 Month PerformanceN/A-3.57%-3.61%-5.73%
1 Year PerformanceN/A-7.13%-0.33%-6.21%

Smart for Life Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SMFL
Smart for Life
N/A$0.00
flat
N/A-98.0%$1K$11.11MN/A110
SISI
Shineco
N/A$0.05
-83.4%
N/A-69.7%$21K$9.60MN/A119
BPTH
Bio-Path
N/A$0.00
flat
N/A-99.7%$16KN/AN/A10
SYRS
Syros Pharmaceuticals
N/A$0.00
flat
N/A-80.0%$11K$386KN/A68
TRVN
Trevena
N/A$0.01
flat
N/A-95.8%$11K$443KN/A23

Related Companies and Tools


This page (NASDAQ:SMFL) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners